Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Steps Drug Makers Must Take Now To Avoid A Post-COVID-19 Manufacturing Crisis

Executive Summary

How pharmaceutical companies should plan to catch up after the pandemic and explain what happened to inspectors.

You may also be interested in...



FDA Prioritizes Shortages Post-Pandemic

Guidance from the FDA urges a focus on restarting production, easing drug shortages and completing quality assurance activities for quarantined batches when the coronavirus pandemic recedes.

US FDA On Resuming Normal Manufacturing Operations When Pandemic Recedes

Focus on restarting production, easing drug shortages and completing quality assurance activities for quarantined batches, agency guidance says.

Responding To FDA 483s And Warning Letters: Some Dos, Don’ts And Red Flags

Invalidated OOS results are ‘red flags’ during FDA inspections and ‘denying, delaying, limiting or refusing’ a drug inspection proposed by the agency could have serious consequence, participants at a recent webinar on best practices for responding to Form 483s and warnings letters heard.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel